PMID- 23361158
OWN - NLM
STAT- MEDLINE
DCOM- 20130916
LR  - 20221207
IS  - 1476-5640 (Electronic)
IS  - 0954-3007 (Print)
IS  - 0954-3007 (Linking)
VI  - 67
IP  - 3
DP  - 2013 Mar
TI  - Effects of high-dose cholecalciferol on serum markers of inflammation and 
      immunity in patients with early chronic kidney disease.
PG  - 264-9
LID - 10.1038/ejcn.2012.217 [doi]
AB  - BACKGROUND/OBJECTIVES: Vitamin D has anti-inflammatory and immune-regulating 
      properties. We aimed to determine if high-dose cholecalciferol supplementation 
      for 1 year in subjects with early chronic kidney disease (CKD) improved 
      circulating markers of inflammation and immunity. SUBJECTS/METHODS: In this 
      double-blind, randomized, placebo-controlled trial, 46 subjects with early CKD 
      (stages 2 and 3) were supplemented with oral cholecalciferol (50 000 IU weekly 
      for 12 weeks followed by 50 000 IU every other week for 40 weeks) or a matching 
      placebo for 1 year. Serum tumor necrosis factor-alpha, interleukin-6, monocyte 
      chemoattractant protein-1 (MCP-1), interferon gamma-induced protein-10 and 
      neutrophil gelatinase-associated lipocalin were measured at baseline, 12 weeks 
      and 1 year. Serum cathelicidin (LL-37) was measured at baseline and 12 weeks. An 
      in vitro experiment was performed to investigate the effect of 
      1,25-dihydroxyvitamin D3 (1,25(OH)2D3) treatment on MCP-1 secretion in THP-1 
      monocytes activated with lipopolysaccharide (LPS) and Pseudomonas aeruginosa. 
      RESULTS: By 12 weeks, serum MCP-1 decreased in the cholecalciferol group 
      (66.2+/-2.5 to 60.8+/-2.6 pg/ml, group-by-time interaction P=0.02) but was not 
      different from baseline at 1 year. Other markers of inflammation and immunity did 
      not change. In vitro, LPS- and Pseudomonas-activated monocytes treated with 
      1,25(OH)2D3 had significantly less MCP-1 secretion compared with untreated cells. 
      CONCLUSIONS: High-dose cholecalciferol decreased serum MCP-1 concentrations by 12 
      weeks in patients with early CKD, although the decrease was not maintained for 
      the remainder of the year. In vitro results confirm an MCP-1-lowering effect of 
      vitamin D. Future studies should determine if vitamin D-mediated reductions in 
      MCP-1 concentrations reflect improved clinical outcomes.
FAU - Alvarez, J A
AU  - Alvarez JA
AD  - Division of Endocrinology, Metabolism and Lipids, Department of Medicine, Emory 
      University School of Medicine, Atlanta, GA 30322, USA.
FAU - Zughaier, S M
AU  - Zughaier SM
FAU - Law, J
AU  - Law J
FAU - Hao, L
AU  - Hao L
FAU - Wasse, H
AU  - Wasse H
FAU - Ziegler, T R
AU  - Ziegler TR
FAU - Tangpricha, V
AU  - Tangpricha V
LA  - eng
GR  - K24 DK096574/DK/NIDDK NIH HHS/United States
GR  - K23 AR054334/AR/NIAMS NIH HHS/United States
GR  - T32 DK007298/DK/NIDDK NIH HHS/United States
GR  - UL1 TR000454/TR/NCATS NIH HHS/United States
GR  - UL1 RR025008/RR/NCRR NIH HHS/United States
GR  - K23AR054334/AR/NIAMS NIH HHS/United States
GR  - T32DK007298-32S1/DK/NIDDK NIH HHS/United States
GR  - K24 RR023356/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20130130
PL  - England
TA  - Eur J Clin Nutr
JT  - European journal of clinical nutrition
JID - 8804070
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antimicrobial Cationic Peptides)
RN  - 0 (Biomarkers)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Interleukin-6)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (dihydroxy-vitamin D3)
RN  - 1406-16-2 (Vitamin D)
RN  - 1C6V77QF41 (Cholecalciferol)
RN  - 82115-62-6 (Interferon-gamma)
RN  - 0 (Cathelicidins)
SB  - IM
EIN - Eur J Clin Nutr. 2013 Nov;67(11):1228
MH  - Administration, Oral
MH  - Aged
MH  - Anti-Inflammatory Agents/administration & dosage
MH  - Antimicrobial Cationic Peptides/blood
MH  - Biomarkers/*blood
MH  - Chemokine CCL2/blood/metabolism
MH  - Cholecalciferol/*administration & dosage/blood
MH  - *Dietary Supplements
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Immunity/*drug effects
MH  - Inflammation/*blood/drug therapy
MH  - Interferon-gamma/blood
MH  - Interleukin-6/blood
MH  - Male
MH  - Middle Aged
MH  - Renal Insufficiency, Chronic/blood/*drug therapy
MH  - Tumor Necrosis Factor-alpha/blood
MH  - Vitamin D/administration & dosage/analogs & derivatives
MH  - Cathelicidins
PMC - PMC3824962
MID - NIHMS492953
COIS- CONFLICT OF INTEREST The authors have no conflicts of interest to declare.
EDAT- 2013/01/31 06:00
MHDA- 2013/09/17 06:00
PMCR- 2013/11/12
CRDT- 2013/01/31 06:00
PHST- 2013/01/31 06:00 [entrez]
PHST- 2013/01/31 06:00 [pubmed]
PHST- 2013/09/17 06:00 [medline]
PHST- 2013/11/12 00:00 [pmc-release]
AID - ejcn2012217 [pii]
AID - 10.1038/ejcn.2012.217 [doi]
PST - ppublish
SO  - Eur J Clin Nutr. 2013 Mar;67(3):264-9. doi: 10.1038/ejcn.2012.217. Epub 2013 Jan 
      30.